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Abstract

The purpose of this review is to investigate the prevalence of documented penicillin
(PCN) allergies in health care and any negative outcomes associated with being labeled as such.
Additional topics researched included the safety and accuracy of PCN allergy testing, the costeffectiveness of PCN allergy testing versus using non-PCN related antibiotics, and barriers to
confirmatory PCN allergy testing implementation. A complete review of the aforementioned
topics included meta-analysis’, systematic reviews, cohorts, clinical trials, and cross-sectional
studies from the last five years. Databases utilized for this research included PubMed, Cochrane
Review, Embase, Dynamed Plus, and ClinicalKey. Sources that were excluded from this review
included opinion-based editorials and those that failed to include analytical review of scientific
research. A total of 18 scholarly sources were utilized for this review. The research revealed a
significant portion of the population is incorrectly labeled as having a PCN allergy when
properly tested. It also showed that having a PCN allergy is associated with increased morbidity
and mortality. Research related to PCN allergy testing indicated high levels of safety and
accuracy. Also, PCN allergy testing costs were found to be significantly lower than those
associated with using alternative antibiotics. Lastly, a majority of the barriers related to
performing PCN allergy testing were largely due to a lack of education on behalf of medical
providers and incorrect perceptions from both patients and medical providers alike. These
findings together indicate that confirmatory PCN allergy testing in the outpatient setting is safe,
accurate, and cost-effective in decreasing the morbidity and mortality associated with having an
incorrect PCN allergy label. However, further research is needed to adequately address the
barriers and incorrect perceptions both providers and patients possess related to PCN allergy
testing.
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Introduction
Penicillin (beta-lactam) allergies are the most commonly reported antibiotic allergies in
the United States, with 10% of the population being labeled as such. However, when tested for
an actual PCN allergy, more than 90% of these patients test negative. Also, 80% of those patients
with a true documented PCN allergy will eventually lose their initial allergy to PCN's after ten
years (Kufel, Justo, Bookstaver, & Avery, 2019). This is significant as having a PCN allergy
label forces clinicians to prescribe alternative and often more broad-spectrum antibiotics that are
associated with increased adverse effects, increased medical costs, increased development of
antibiotic resistance, and worse clinical outcomes (Kufel et al., 2019). These negative outcomes
could be avoided if patients with PCN allergies were safely and accurately tested to confirm or
deny the presence of an actual PCN allergy. Unfortunately, of those clinicians that have
antibiotic allergy testing (AAT) services available to them, 40% were unaware of the specific
types of testing available to them when surveyed (Trubiano et al., 2016). This is one of the
barriers that prevents clinicians from referring patients for PCN allergy testing. The purpose of
this study is to highlight the cost-effectiveness, safety, and accuracy of confirmatory PCN allergy
testing in reducing the increased morbidity and mortality associated with having an unconfirmed
documented PCN allergy.
Statement of the Problem
Patients with a history of PCN allergy are at an increased risk for also reacting to betalactam antibiotics in the cephalosporin and carbapenem groups. Specifically, there is a 5-10%
chance of cross-reactivity to cephalosporins and a relatively low risk of reaction with
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carbapenems at 1% (Papadakis, McPhee, & Rabow, 2019). Unfortunately, this removes three
significant families of antibiotics that can be prescribed to a patient with an unclear or
unconfirmed history of a PCN allergy. Avoiding use of beta-lactams or similar antibacterial
agents due to a reported unconfirmed PCN allergy has been shown to increase hospital
readmissions and adverse drug outcomes compared to patients without a PCN allergy (DynaMed
Plus, 2018). Also, patients with a documented PCN allergy have an increased risk of methicillinresistant Staphylococcus aureus (MRSA) infections and Clostridioides difficile infections (CDI).
This is unfortunate as the overall safety of PCN allergy testing has been well documented as
being safe in many patients, including pregnant women, patients requiring organ transplants, and
children (DynaMed Plus, 2018). This means that clinicians could safely and significantly lower
the increased morbidity and mortality associated with having an unconfirmed PCN allergy label
by recommending and referring patients for confirmatory PCN allergy testing in the outpatient
setting.
Research Question
In otherwise healthy patients with an unclear or unconfirmed history of PCN allergy,
would confirmatory PCN allergy testing in the outpatient setting versus using more broadspectrum antibiotics not related to PCN's be more cost-effective and safer in limiting overall
patient morbidity and mortality?
Methodology
Studies included in the review of research were limited to the last five years in both the
United States and abroad. Editorials and other opinion-based articles were eliminated.
Databases searched included: PubMed, Cochrane Review, Embase, Dynamed Plus, and
ClinicalKey. MeSH terms used to populate relevant research included: penicillin allergy, β-
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lactam allergy, allergy testing, penicillin, penicillin testing, penicillin cost, and penicillin allergy
risks. The population of patients this research focused on included men, women, and children of
varying ages with a documented PCN allergy in their medical records. Research studies reviewed
included meta-analysis’, systematic reviews, cohorts, clinical trials, and cross-sectional studies.
This thorough review of studies ultimately focused on the prevalence of incorrect PCN allergies;
the morbidity and mortality associated with having an incorrect PCN allergy; the safety and
accuracy of PCN allergy testing; the cost-effectiveness of PCN allergy testing, and any barriers
to the implementation of PCN allergy testing.
Review of Literature
An extensive and thorough literature review shows there is a significant amount of research
indicating the prevalence of patients having an incorrect PCN allergy label when properly tested
(Kufel et al., 2019). In addition to this, current research indicates elevated levels of patient
mortality and morbidity associated with having an incorrect PCN allergy label (West et al.,
2019). Other research proves the overall safety, accuracy, and cost-effectiveness of PCN allergy
testing. Lastly, the current research indicates several barriers as to why PCN allergy testing is
not routinely being performed in the outpatient setting. These include physician and patient
misconceptions regarding PCN allergy testing and an overall lack of knowledge on medical
providers’ behalf regarding confirmatory PCN allergy testing (Trubiano et al., 2016).
The Prevalence of an Incorrect Penicillin Allergy
PCN allergies are one of the most common allergies reported to medical providers in the
outpatient and inpatient setting. In fact, 10% of the United States population is labeled as having
a PCN allergy. However, when properly tested, more than 90% of these patients actually test
negative for a PCN allergy (Kufel et al., 2019). Several reasons may account for this including
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but not limited to: unverified allergic reactions reported to patients by their parents during
childhood, incorrect patient recall of the allergic reaction, and incorrect medical recording of
reactions. Another factor that may account for these staggering statistics lies in the fact that 80%
of patients who do have a true documented PCN allergy will eventually lose their PCN allergy
after a period of ten years (Kufel et al., 2019). So, even those patients who are correctly
identified as having a known PCN allergy will likely test negative eventually.
Kleris, Tang, Radojicic, and Lugar instituted a clinical trial in the form of a pilot clinic in
May of 2017 to test the feasibility of a dedicated outpatient PCN testing clinic (2018). This was
done to address the negative issues related to having an unconfirmed PCN allergy. The pilot
clinic was created in May of 2017 using an allergist and an allergy registered nurse trained in
penicillin skin testing (PST). Their method of PCN testing consisted of a history and physical
reviewing the details of the patient’s PCN reaction, skin prick testing, intradermal testing, and a
two-step graded challenge with amoxicillin (400 mg). Each of these tests was dependent upon
the negative result of the prior test in order to proceed to the next test. The patients were
observed for 30 minutes following each graded challenge for any reactions. If no reaction was
observed during the graded challenge, then the patient’s PCN allergy status was removed from
their medical records.
During the first year of their pilot program, a total of 104 patients were evaluated. Of
these patients, the most commonly reported PCN reaction was hives or rash (83 patients
[79.8%]) followed by an unknown reaction (11 [10.6%]). A majority of the patients (87
[84.5%]) reported reactions that had occurred 10 or more years prior. The mean of ages tested
was 54.4 years of age plus or minus 16.7 years. Of those patients, 35 were male (33.7%), 69
were female (66.3%), 78 were white (75.7%), 23 were black (22.3%), 1 was Hispanic (1%), and

PENICILLIN ALLERGY TESTING

9

1 was of other race (1%). The number of reactions to different types of PCN’s and related
antibiotics reported by patients was as follows: 45 (43.3%) to PCN, 19 (18.3%) to
Amoxicillin/Augmentin, 34 (32.7%) to an unknown PCN, and 5 (4.8%) to a Cephalosporin.
Finally, patients tested with other known comorbidities were as follows: 44 patients with cardiac
disease (42.3%), 43 patients with pulmonary disease (41.3%), and 20 patients with oncologic
disease (19.2%).
The results of their testing revealed a total of 95 patients (91.3%) with negative PCN skin
testing. Four patients had a positive intradermal skin test and therefore were not challenged any
further. Of the patients with a positive skin test, none reported/ experienced anaphylaxis. A total
of 99 (95.2%) out of 104 patients with a reported PCN related allergy passed the final graded
oral challenge and were therefore cleared of their PCN allergy.
Limitations of this study are that it did not include many pediatric patients and its results
were limited to one year with no follow up testing to evaluate for any return of PCN sensitivity.
This study is noteworthy as it demonstrated that a majority of patients with a reported PCN
allergy were actually not allergic to PCN’s when properly evaluated. It also shows that graded
PCN testing safely, accurately, and efficiently identified patients with a negative PCN allergy in
the outpatient setting.
Another study that was performed by Moussa et al. involved a multi-step semiprospective clinical trial to evaluate the potential value of de-labeling patients with a beta-lactam
allergy. Patients included in this study had a PCN allergy noted in their electronic medical
record (EMR) and who were scheduled for an upcoming surgery (2018). Surgical patients are
often given intraoperative prophylactic antibiotics to improve surgical outcomes. The authors of
this study wanted to evaluate if beta-lactam de-labeling optimized the choice of prophylactic
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antibiotics and ultimately improved intraoperative time and efficiency. Their method of study
began by establishing a service and protocol to provide perioperative evaluation of patients
identified via EMR with a possible beta-lactam allergy at Montreal General Hospital. Eligible
study participants were adults (eighteen years of age or older) who had a history of an allergic
reaction to penicillin and who were scheduled for elective surgery within six months following
the date of their preoperative visit. These patients were then evaluated using standardized
prescriptions, policies, procedures, and a risk assessment tool. Study participants were given a
tiered graded PCN testing approach based on their risk assessment for anaphylaxis. This
consisted of skin prick testing, intradermal testing, and an oral challenge provided they were
negative for a reaction with the previous test. The testing was performed in an outpatient
interventional allergy care unit with an allergist present to evaluate for any reactions following
their last dose of PCN challenge. Patients, if cleared of reaction after two hours of observation,
were then required to call 24 hours post-testing to report any possible delayed reactions.
A total of 194 study participants were identified using EMR. The cohort portion of the
study involved 129 females (66.5%) and 65 males (33.5%). Study participants had a previously
reported reaction to PCN or a related PCN antibiotic within the past five years (4.6%), between
5-20 years ago (18.6%), or more than 20 years ago (50%). The remaining patients (26.8%) had
an unknown or undocumented date of a PCN allergy reaction. A majority of the reported
reactions to PCN’s was an unspecified rash (29.9%) and urticaria (20.1%). The types of surgical
patients varied from orthopedic, general, thoracic, plastic, and maxilla-facial.
Results of the study were as follows: of the 194 study participants, four had a positive
skin test and were not orally challenged and 44 had a negative skin test and were not orally
challenged based on their low-risk assessment. This was due to the extremely low likelihood of
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them having a PCN reaction. Of the 146 remaining patients who were systematically evaluated
using skin testing and oral drug challenge, only seven patients were positive for a reaction.
Ultimately, eleven individuals were positively identified as having a confirmed beta-lactam
allergy. This meant that 183 out of 194 (94.3%) of the study participants were successfully and
safely de-labeled from having a documented beta-lactam allergy. Antibiotic use both
preoperatively and prophylactically in the study patients was as follows: of the 139 patients with
a negative challenge, 19 did not require preoperative antibiotics and cefazolin was prescribed to
102 of the remaining patients. Cefazolin is a beta-lactam antibiotic of the cephalosporin family,
which is related to the PCN family of antibiotics and otherwise would not have been prescribed
due to its close relation to PCN’s. Of the 44 patients with a negative skin test who were not
given an oral challenge, eight did not require prophylactic antibiotics and cefazolin was
prescribed in 18 of the remaining 36 patients (50%).
Some of the limitations of this study were that it relied on data that was subject to poor
patient recall or incomplete data entry related to penicillin versus amoxicillin reactions. The
study also failed to evaluate patients who were not referred for preoperative allergy evaluation or
who were given antibiotics outside of the ones noted in the study. Overall, this study exhibited
that patients can safely and effectively be de-labeled from having a PCN allergy and that a
majority of patients with a documented/ reported PCN allergy were actually not allergic when
tested.
Morbidity/ Mortality Associated with a Penicillin Allergy
It is well established that having a documented PCN allergy results in patients being
placed on alternative antibiotics that are often more broad-spectrum. These broad-spectrum
antibiotics have been associated with increased adverse effects, worse clinical outcomes, and
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increased development of antibiotic resistance (Kufel et al., 2019). All of these factors
contribute to patients having an increased risk for morbidity and mortality when compared to
those patients who are not documented as being PCN allergic.
This is well demonstrated by a series of cross-sectional/ retrospective cohort studies
performed by West et al. to determine the prevalence of PCN allergy records in the United
Kingdom, any patient characteristics associated with PCN allergy records, and the ultimate
impact of PCN allergy records on antibiotic prescribing/ health outcomes in primary care settings
(2019). This research was also performed to support a “preemptive” testing strategy for the
presence of an actual PCN allergy. The method of study involved three parts: part one was a
cross-sectional study of adult patient EMR’s identifying any factors associated with a PCN
allergy; part two was a retrospective cohort of the patients in part one looking for the potential
impacts of a PCN allergy on several health outcomes including asthma, cancer, congestive heart
disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, peripheral
artery disease, stroke, and transient ischemic attack; and part three was a retrospective cohort that
only included those patients prescribed at least one antibiotic during the study year. The study
group included all adults aged 18 to 100 years with EMR’s on ResearchOne and those patients
who had died since April 1st, 2013. Study participants were considered to have a PCN allergy if
their EMR included either a sensitivity or an allergy to any PCN class antibiotic agent, including
amoxicillin, ampicillin, penicillin V and G, flucloxacillin, and piperacillin. Health care
outcomes measured included associated infections such as MRSA, CDI, and vancomycinresistant enterococci (VRE). If a record of prescription of a subsequent antibiotic of a different
class was prescribed within 28 days following the prescription of one the monitored antibiotics,
it was considered a lack of treatment response.
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A total of 2,350,803 adult patients met the initial inclusion criteria of the study. Of those
patients, 139,437 patients had a PCN allergy recorded in their EMR which gave a prevalence for
the population of 5.9% (95% CI 5.9-6.0%). It was discovered women were more likely to have a
recorded PCN allergy (7.4%) and the prevalence of this increased significantly with increasing
age (8.5% of patients aged 75-100 years of age). The monitored comorbidities had a small, but
significant increased likelihood of having a PCN allergy record with asthma having the highest
(8.9%). In the second part of the study, patients with a PCN allergy record received
approximately 5% more antibiotic prescriptions than those without a PCN allergy record during
a 12 month follow up. Antibiotics, including macrolides, tetracyclines, cephalosporins,
quinolones, clindamycin, nitrofurantoin, and trimethoprim were all prescribed significantly more
in patients with a documented PCN allergy. The top three most prescribed antibiotics were
clindamycin with a relative rate (RR) of 5.47 (p<0.001), macrolides with a RR of 4.03 (p<0.001),
and quinolones with a RR of 2.10 (p<0.001).
When compared with those patients without a recorded PCN allergy, those with a
recorded PCN allergy had a significantly increased risk of death in the following year at 2056
patients (1.5% [p<0.001]), re-prescription of a new antibiotic class within 28 days at 10,111
patients (7.3% [p<0.001), and MRSA infection/ colonization at 95 patients (0.1% [p<0.001]).
This meant a PCN allergy record was associated with 6 in 1000 more deaths and 1 in 1000 more
patients with documented MRSA infections/ colonization. There was a non-statistically
significant increase risk of CDI at 26 patients (p-value 0.027). Overall, a documented PCN
allergy affected 1 in 17 general practice patients. A PCN allergy was associated with increasing
age, comorbidity, and being female. Also, a PCN record was associated with more antibiotic
prescriptions, different antibiotic prescribing profiles, a higher rate of re-prescription of
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antibiotics within 28 days, a greater risk/ burden of MRSA infections/ colonization, and an
increased risk of death.
The limitations of the study relate mainly to its method of data collection. The use of
routinely collected clinical data such as allergic reactions carries a risk of bias. The authors may
have missed other conditions that were affected by having a PCN allergy but were not recorded.
It is also important to note that the use of electronic data is at risk of bias due to issues with data
migration, patient recall, documentation differences, and the variability of reported drug
reactions. However, this study does provide compelling evidence that documented PCN
allergies are associated with an increased amount of antibiotic prescriptions, different antibiotic
prescribing profiles, increased rates of repeat antibiotic prescriptions within 28 days of initial
treatment, a greater risk of MRSA infection, and an increased risk of mortality.
A similar study was a population-based matched cohort study performed by Blumenthal
et al. (2018). The authors sought to evaluate the relationship between having a PCN allergy and
the development of MRSA and CDI. This study performed in the United Kingdom utilized
EMR’s to identify patients older than 18 years of age who had a PCN allergy documented with
no known exposures or incidences of CDI or MRSA within the last year. This group was then
compared to other patients of similar characteristics without a known PCN allergy for the
development of CDI and MRSA.
A total of 64,141 patients with a PCN allergy and 237,258 patients without a PCN allergy
were studied over a period of 6 years. Of the PCN allergy patients, 442 developed MRSA and
442 developed CDI. Of those patients without a PCN allergy, 923 developed MRSA and 1,246
developed CDI. The adjusted hazard ratio for MRSA was 1.69 (95% CI, 1.51 to 1.90) and 1.26
for CDI (1.12 to 1.40). Overall, having a PCN allergy label accounted for a 68% increased risk
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of MRSA and a 26% increased risk for CDI. The use of non-PCN related antibiotics accounted
for 55% of the increased risk for MRSA and 35% for the increased risk of CDI. It was also
discovered that a PCN allergy label results in a four-fold increased incidence in macrolide and
clindamycin use and a two-fold increase in fluoroquinolone use. Lastly, half of the increased
risk of MRSA and more than one-third of the increased risk of CDI among patients with a PCN
allergy was attributable to the use of antibiotics other than beta-lactams.
Some of the limitations of this study are that it relies on EMR data, which can be subject
to data entry errors and patient recall bias. It also failed to test the PCN allergy patients to ensure
they had a true PCN allergy. That being stated, the study did exhibit an increased incidence and
risk of MRSA and CDI in patients with a documented PCN allergy largely due to the use of
alternative antibiotics not related to PCN’s. It also showed that a PCN allergy label increases a
patient’s risk of being prescribed more broad alternative antibiotics.
Macy and Shu (2017) completed a study that was a matched cohort study of PCN allergic
patients who had not been tested to confirm a PCN allergy (308) and PCN allergic patients who
had been tested and were found to be negative for a documented PCN allergy (1251). This was
done to evaluate the effect of PCN allergy testing on future health care utilization. Health care
utilization was measured by outpatient department visits (OPD), emergency department (ED)
visits, and days spent in the hospital. The authors method of study included utilizing EMR data
in the Kaiser Permanente Southern California area. The average time of follow up was 3.6 and 4
years. Results of the study showed that during the time period of study, PCN allergy-tested
patients averaged 0.09 fewer OPD visits (p<0.001), 0.55 fewer hospital days (p<0.001), and 0.13
fewer ED visits. The PCN tested patients were also found to be prescribed more PCN’s and
second-generation cephalosporins with fewer prescriptions for clindamycin and macrolides.
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Both clindamycin and macrolides being more broad-spectrum antibiotics with increased risks for
adverse effects.
The limitations of this study are similar to other studies in that it relied on data that is
subject to possible documentation errors and patient recall bias. Overall, this study reveals both
the cost-saving benefits and decreased health care utilization associated with successfully being
PCN allergy de-labeled.
Another study completed in 2017 sought to identify whether PCN allergy testing affected
patient clinical outcomes during hospitalization. This systematic review was performed by
Sacco, Bates, Brigham, Imam, and Burton using an electronic search of literature from the past
20 years including Ovid MEDLINE/ PubMed, Embase, Web of Science, Scopus, and Cochrane
Library (2017). Inpatients with a documented PCN allergy who underwent PCN allergy testing
while hospitalized were included in the study. Overall, 24 studies met their criteria with sample
sizes ranging between 24 and 252 inpatients. PCN skin testing with/ without oral amoxicillin
challenge was the main intervention.
The population weight mean for a negative penicillin skin testing (PST) was 95.1% with
a CI of 93.8 to 96.1. It was found during their review of studies that a significant change in
prescribing more narrow antibiotics was noted following PST. This was greatest in the inpatient
ICU setting (77.97%; CI 72.0-83.1) versus the general inpatient population (54.73%; CI 51.258.2). It was mentioned that this could be due to providers in the ICU setting having to treat
more complex patients with organ failure giving them an incentive to rule out an incorrect PCN
allergy to aid in treatment. Greater mortality, morbidity, and health care costs in the ICU
associated with antibiotic resistance were also cited as possible reasons for increased PST in the
ICU. It was also noted that there was a rise in PCN (range 9.9% to 49%) and cephalosporin
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(range 10.7% to 48%) prescriptions following PCN testing. A decrease in vancomycin and
fluoroquinolone use was found to be present in all studies with an increase in PCN and
cephalosporin prescriptions following PST noted.
Some of the limitations of this review are that it largely relied on observational cohort
studies and not higher levels of evidence such as randomized control trials. This study was also
limited to only inpatients and did not include patients outside of the hospital. Overall, this study
shows that PCN allergy testing leads to positive changes in antibiotic prescribing habits, such as
prescribing more narrow-spectrum antibiotics. It also shows a statistically significant number of
inpatients with a documented PCN allergy who underwent PST were actually negative at 95.1%.
The Safety and Accuracy of Penicillin Allergy Testing
The safety and accuracy of PCN allergy testing in the outpatient setting is of the utmost
importance when attempting to convince patients and providers alike of its benefits. If a patient
were to be incorrectly de-labeled from having a PCN allergy he or she may experience a lifethreatening anaphylactic reaction if then given PCN. Bourke, Pavlos, James, & Phillips
performed a clinical trial in Australia from 2008 to 2013 to evaluate the effectiveness of PCN
allergy de-labeling in clinical practice (2015). This was done to develop further risk
stratification models to guide future testing strategies. Patients aged 15 years or older were
referred to a Western Australia public hospital drug allergy service for beta-lactam allergies. A
total of 405 patients were referred to tertiary care public hospitals to undergo skin prick testing
(SPT), intradermal testing (IDT), and/ or amoxicillin oral challenge (OC) testing to evaluate their
reported beta-lactam allergy. Information was collected prior to testing which included: the
reported antibiotic allergy, the timing and nature of the reaction, comorbidities, and any comedications. Results and reactions were later reviewed following testing to classify reactions as
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being immediate (likely IgE mediated, ≤ 1 hour), accelerated (possible IgE reaction, ≤ 72 hours),
delayed (non-IgE mediated, any reaction >72 hours), or other. IgE mediated reactions are acute
anaphylactic reactions which can be dangerous to a patient’s health. Any patients with a past
history relating to a delayed reaction with severe systemic, cutaneous, mucosal, or organ
involvement were not included in the study. Testing for beta-lactam allergies was conducted per
recommended guidelines using a graded challenge consisting of SPT, IDT, and/ or OC testing
based on the patient’s history of results from subsequent tests.
The mean age of patients in the study was 47.4 years (range 15-85 years) with 272 female
patients (67.1%) out of 401 total patients. Patients were classified based upon their most recent
known reaction. Of the 401 patients, 151 (37.7%) were classified as immediate reaction (IMM,
≤ 1 hour from dosing) and 250 patients as being non-immediate reactions (NIM >1 hour). Out of
a total of 341 patients, 42 (12.3%) were SPT/IDT positive to ≥1 PCN reagents per their medical
history. This included 35/114 (30.4%) in the IMM group and 7/227 (3.1%) in the NIM group
(p<0.0001). The most common beta-lactam related antibiotic reactions reported were as follows:
PCN (n=181), amoxicillin (n=94), amoxicillin-clavulanate (n=49), and cephalexin (n=56). It
was also noted that 60 (15%) of patients reported having a previous reaction to ≥ 2 different
beta-lactam related antibiotics.
Skin testing was performed within six months of reaction in 108/401 (26.9%) of patients,
six to twelve months in 52/401 of patients (13%), one to five years in 54/401 of patients (13.5%),
5 to 10 years in 24/401 of patients (6%), and after more than ten years in 163/401 of patients
(40.6%). In patients with a history of multiple reactions, their most recent date of reaction was
used. Patients who were skin tested ≤ 6 months since their reaction (27/73 [37%], p<0.0001))
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and in the IMM group (35/112 [31.3%], p< 0.0001) had the highest proportion of positive skin
results when compared with the other patients.
Results of the study showed that out of the patients that were tested with SPT/ IDT, three
(0.8%) in the IMM group had non-serious positive OC reactions to a single dose of PCN VK
(SPT/IDT negative predictive value (NPV) 99.2%). Overall, selective or unrestricted betalactam use was recommended in almost 90% of study participants. This included 238/250
(95.2%) in the NIM group and 126/151 (83.4%) in the IMM group (p=0.0001). Patients were
contacted following the clinical trial (median 15 months) and assessed whether or not they were
following their new recommended guidelines for or against beta-lactam use. Of 182 patients
contacted, 137 (75.3%) were following their allergy label modifications (ALM) at the time of
follow-up. And of those patients, 101 had subsequently received antibiotics following the study
with only 17 (16.8%) reporting a subjective adverse drug reaction (ADR). None of these
reactions were IMM reactions and it was not always possible to confirm these reports or the
antibiotics responsible.
Limitations of this study are mostly due to bias in reporting from patients. Often, a
patient’s recollection of past events can be skewed and even the follow-up evaluation for drug
reactions since being de-labeled largely relied on subjective reports which could not be verified.
That being said, this study does add more evidence supporting the prevalence of incorrect PCN
allergy labels in the medical field and the accuracy of tiered/ graded PCN allergy protocol
testing. Selective or unrestricted beta-lactam use was recommended in almost 90% of the
study’s subjects after testing. It was also noted that the NPV of beta-lactam allergy using
SPT/IDT was 99.2%. Lastly, 75.3% of study participants were following their new allergy label
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modifications at the time of follow up. This shows patients can be trusting of the testing
protocols and procedures in relation to PCN allergy testing.
A retrospective review was recently completed by Dorman, Seth, and Khan between the
years of 2010 and 2016 of adult patients at the University of Texas Southwestern Medical Center
hospitals and clinics (2017). The patients studied had previously tested negative with PCN
allergy testing. They specifically sought to evaluate the risk of allergic reactions to repeated
doses of intravenous (IV) PCN’s in patients who had previously tested negative to PCN SPT and
amoxicillin OC testing. Medical records were reviewed in those patients who had been given
two or more courses of IV PCN’s since having tested negative for PCN allergies. A “course” of
IV PCN administration was defined as being as little as a single dose or as long as needed to treat
the illness as long as there was not a break-in dosing longer than seven days in duration. After
each PCN type antibiotic administration, the subject’s EMR was reviewed for any evidence of
immediate allergic reactions or any delayed adverse drug reactions (ADR’s).
The study included 32 subjects with four having undergone PCN allergy testing in an
ambulatory setting and 28 in a hospitalized setting. Seventeen subjects (53%) were women and
the average age at PCN skin testing was 46.9 years (range 24-79 years). Differences in race
were as follows: 13 identifying as black, 10 white, 3 Hispanic, and 6 of unknown race. A
majority of the subjects (75%) had historical reactions to PCN’s greater than ten years prior and
16% reported a reaction to PCN within a year of PCN allergy testing taking place. A majority of
the reported reactions to PCN’s were some type of cutaneous reaction.
The total number of parenteral PCN courses reviewed was 111. This broke down further
to a mean of 3.5 courses per patient (range 2-12 courses). A total of more than 50% of patients
received three or more courses of IV PCN’s. The types of IV PCN’s patients were exposed to
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included: ticarcillin, nafcillin, ampicillin, penicillin G, and piperacillin. The most common
antibiotic given was piperacillin (30/32 subjects) and the least common was penicillin G with
only one patient being exposed once. The median time between the negative PCN skin testing
and the first IV course of PCN’s was 19 days (range 1-933 days). And the time from negative
PCN skin testing to the second course of IV PCN’s was a median of 129 days (range 14-1055
days).
The results of the study showed that there were no documented IMM reactions identified
in those who had tested negative for PCN allergies and then treated with repeated doses of IV
PCN’s. Three subjects reported delayed adverse reactions, including subjective throat pruritis
(one), acute interstitial nephritis (one), and benign exanthema (one). Overall, the estimated
reaction rate was 0% with a 95% CI of 0% to 3.3% to 11%. The varying range of the upper limit
of the CI is directly related to how one chooses to perceive the sample size. This being if each
PCN course (N=111, CI 3.3%) is treated separately or each patient involved in the study is
counted (n=32, CI 11%).
Some of the limitations of this study are related to its somewhat small sample size, but
more than 50% of the study’s participants did receive three or more courses of IV PCN’s. It also
relies solely on a retrospective review of EMR documentation. This is subject to significant bias
in reporting and documentation. Also, a majority of patients were observed in the inpatient
setting and any possible delayed allergic reactions may have been missed or under-reported.
This study is significant in that it reveals both the overall accuracy of PCN allergy testing/ delabeling and the safety of such testing. It goes further to show that re sensitization following
PCN allergy testing is less likely. Finally, it shows that repeated PCN allergy testing following
negative skin testing and IV PCN administration is not necessarily warranted, provided both
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were tolerated by the patient without any allergic reaction. Larger studies will need to be
performed to confirm further this study’s results, which were largely based on a small population
of patients.
Another study seeking to evaluate the safety and accuracy of PCN allergy testing was a
five-year institutional retrospective study that was performed using adult patients (age ≥18 yearsof-age) who were evaluated by allergists-immunologists at a local affiliate hospital and
outpatient practice (Mawhirt, Fonacier, Calixte, Davis-Lorton, & Aquino, 2016). These patients
were initially evaluated between the years of 2009 and 2014. The main objective of this study
was to evaluate any relationship between a patient self-reported antibiotic hypersensitivity
history and subsequent skin testing results during an allergy evaluation of those patients.
Specifically, the authors were seeking to “(1) identify putative risk factors for antibiotic drug
challenge reactions, (2) analyze the relation between the reported index reaction severity and the
observed challenge reaction severity, and (3) examine the safety and outcomes of single-step and
multistep challenge methods” (Mawhirt et al., 2016). The primary study method involved the
authors gathering the patient population using inpatient and outpatient billing records and a
search of an allergy-immunology consultation log book. Only patients with a clinical history
positive for prior immediate-type hypersensitivity reactions were included in the study. Further
data including patient age, sex, atopic disease, type of antibiotic reaction, reaction severity, route
of administration, and treatments received was collected and reviewed from the patients’
electronic medical records.
A total of 211 patients with a documented antibiotic immediate-type hypersensitivity
reaction history who underwent allergy consultation were identified. The median age was 67
years (range 50-76 years) with 58% being women. Multiple families of antibiotic reactions were
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included, but for the purposes of this study, the beta-lactam antibiotics and related families were
focused on. Of those patients, 165 (78%) reported reactions to PCN’s (penicillin, amoxicillin or
piperacillin-tazobactam), 16 (7.6%) to cephalosporins including first-generation through fifthgeneration cephalosporins, and 8 (3.8%) to carbapenems (meropenem, ertapenem, and
imipenem). A majority of patients reported a reaction having resulted from an oral route of
administration (44%) and a non-anaphylactic (71%) type reaction (grade 1 or 2). A total of 141
patients received SPT/IDT for their respective antibiotic allergy. Of those patients receiving skin
testing (positive versus negative reactions) were 4 vs. 49 for PCN’s, 1 vs. 52 for cephalosporins,
and 0 vs. 31 for carbapenems. A majority (125 of 134) of patients with a negative skin test went
on to receive a further antibiotic challenge.
Results of the study were as follows: patients with a reported PCN allergy who completed
the challenges showed a high tolerance to other PCN’s (88%), cephalosporins (96%), and
carbapenems (90%). Overall, 179 patients in total completed the allergy challenges with a
median age of 67 years, a range of 50-76 years, and 58% of those patients were women. Of
those patients, 16 (8.9%) experienced challenge reactions with 5/28 patients for a single-step
challenge and 11 of 151 for a multistep challenge. Eleven of these patients had negative skin
allergy testing prior to the challenge. It was also noted that challenge reactive patients were
“significantly” younger (p=0.007), more likely to be female (p=0.036), and more likely to have
additional reported antibiotic allergies (p=0.005). The route of administration of antibiotics and
the severity of their reaction failed to yield any correlation (k=-0.05, 95% CI of -0.34 to 0.24).
Also, the rates of anaphylaxis observed with single step and multistep challenges were similar
with 3.6% vs. 3.3%, respectively.
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Limitations of this study are that it centered on a retrospective design that relies on EMR
and often subjective patient histories. The risk of patient recall bias is significant, and the
smaller sample size limited the data available for further comparing two-step and three-step
challenge results. This study is unique in that it specifically sought to evaluate the outcomes
related to skin testing and oral challenges only in those patients with a history of an antibiotic
immediate-type reaction. It also reviewed the safety and outcomes of skin and oral challenge
testing in those patients. This study helps support the necessity of graded allergy testing as
negative skin testing in this study did not exclude the possibility of oral challenge reactions. It
also shows that a patient’s reported severity of an initial allergic reaction was not predictive of an
oral challenge outcome. Finally, the risks of anaphylaxis during multistep and full dose methods
of allergy testing showed similar risks of reaction, which supports both methods being suitable
testing methods based on history and physical exam.
Another study performed in 2012 by Mill et al. sought to assess the accuracy of a graded
provocation challenge (PC) of amoxicillin in diagnosing immediate and nonimmediate allergic
reactions in children with a suspected amoxicillin allergy (2016). The study design included both
a retrospective and a prospective portion. Children that were referred to the allergy clinic of the
Montreal Children’s Hospital with a suspected allergy to amoxicillin were included in the study,
including those with a past reaction history consistent with anaphylaxis. Any children with
suspected reactions relating to Stevens-Johnson syndrome or toxic epidermal necrolysis were not
included. Consent was obtained from children’s parents and a standardized questionnaire was
completed by the parents. The questionnaire included questions related to comorbidities,
suspected antibiotic exposures, and management of the reaction they experienced. All pediatric
patients consenting were then given a graded PC (10% of the therapeutic dose of amoxicillin,
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then 90% of the therapeutic dose was given 20 minutes later). The children were then observed
for at least one hour following their last dose. The authors of the study also followed the patients
following the PC to assess for any further amoxicillin use or amoxicillin reactions. An allergic
reaction within one hour of the PC was labeled as having an immediate antibiotic allergy. These
symptoms included urticaria, wheezing, rhinitis, vomiting, diarrhea, abdominal pain, or shock.
Non-immediate reactions were described as any symptoms including arthritis and arthralgia
more than one hour after PC and up to one week later.
From March 2012 and April 2015, 818 study participants underwent amoxicillin PC. The
median age was 1.7 years (interquartile range, 1.0-3.9 years) and 441 (53.9%) were males.
Three groups of study were separated following testing to include: those tolerant of PC, those
with an immediate reaction to PC (< 1 hour), and those with a nonimmediate reaction to PC (>1
hour). The results of the study showed that 770 (94.1%) of the children tolerated PC. There
were 16 patients with an immediate reaction consisting of hives, but all resolved within a few
hours of treatment with second-generation antihistamines. The third group of children consisted
of 31 total patients (3.8%) with nonimmediate type reactions to PC. Those reactions were mild
and varied from a maculopapular rash with angioedema to serum-like sickness reactions. The
median of time from PC and a delayed reaction was 12 hours (29%; 95% CI, 14.9%-48.2%).
A total of 250 patients (72.3%; 95% CI, 67.2%-76.8%) were successfully followed up with after
the completion of PC testing via a telephone call. Of those patients, 55 had received subsequent
full treatment with amoxicillin with 49 of them (89.1%) tolerating full treatment and 6 (10.9%)
experiencing a delayed skin reaction. Ultimately, it was discovered that graded PC had a
specificity of 100.0% (95% CI, 90.9-100.0%), a NPV of 89.1%, and a positive predictive value
(PPV) of 100.0% (95% CI, 86.3%-100.0%).
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The limitations of this study are that it was limited to pediatric patients and it did not
include adults. This means that amoxicillin was mostly evaluated and no other forms of betalactam containing antibiotics commonly prescribed to adults. Other studies reviewed so far have
indicated increased incidences of reactions with allergy testing in pediatric patients vs. adult
patients, which may skew this study’s findings. Lastly, in addition to other studies reviewed, this
study relied on the parents recall of allergic reaction variables via questionnaire and are therefore
subject to information and recall bias. This study is significant as it shows the high levels of
specificity, NPV, and PPV of graded PC with amoxicillin in children. This study also showed
that a majority of children suspected of having an amoxicillin allergy are actually negative when
tested using a graded PC with amoxicillin, which supports the prevalence of an incorrect PCN
allergy in children.
A clinical trial to evaluate the feasibility of offering PCN allergy testing to outpatients
regardless of their chief complaint was completed by two allergy/ immunology physicians at an
outpatient practice between April 2017 and June 2017 (Ramsey & Mustafa, 2018). During their
trial, they collected a PCN allergy history from patients and skin testing and/ or challenge testing
was offered based on the patient’s allergy history obtained. PST and IDT were performed and
then if negative, an oral amoxicillin challenge was given with patients being monitored in the
clinic for any reactions for 30 minutes after. A total of 978 patients were screened for PCN
allergies with 150 (15.7%) patients reporting a PCN allergy. The average age range of patients
was 32.4 ± 23.6 years. Ninety-six (61.9%) of patients positive for PCN allergy were female.
The leading reasons for patients presenting to the allergy/ immunology clinic were PCN or
multiple drug allergy (n=38; 24.5%), asthma (n=35; 22.6%), chronic rhinitis (n=32; 20.6%), and
food allergy (n=21; 16.8%). Forty-six patients (49%) reported that more than ten years had
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passed since their last known reaction, five to ten years in 19 patients (12.3%), more than one to
five years in 33 patients (21.3%), and one year or less in 16 patients (10.3%). Eleven patients
did not recall when their reactions occurred. The top reaction histories included rash in 82
patients (52.9%), hives in 45 patients (29%), dyspnea in 3 patients (1.9%), angioedema in 3
patients (1.9%), anaphylaxis in 2 patients (1.3%), and itching in 2 patients (1.3%).
A total of 66 out of 155 patients (42.6%) were administered PST. Of those patients,
58/66 (87.9%) were PST negative and all of those 58 patients then underwent an oral challenge.
All skin prick tests were negative in the PST positive patients. Three patients had a positive
IDT. The average time for the entire PST and oral challenge was 71.1 minutes ± 12 minutes.
Two patients (1.3%) received a same-day oral challenge without PST and six patients (3.9%)
were de-labeled solely on the basis of history. Only one patient experienced nausea and
vomiting starting two hours after PST and oral challenge. In total, 66 of 155 (42.6%) of patients
with a reported PCN allergy were successfully and safely de-labeled.
This study demonstrates PCN allergy testing can safely and efficiently be performed in
the outpatient setting even using less than the recommended staff and observation times. The
authors of this study cited similar studies with increased attrition rates due to prolonged allergy
testing protocols. This study’s authors avoided increased rates of attrition by having a shorter
window of testing and observation. The limitations of this study are related to its setting and
expertise. While it is true that only two providers were able to successfully test and de-label
PCN allergic patients, it does not mean all providers outside of allergy/ immunology would be
comfortable or financially able to do so also. This study also suffers as other studies do to recall
and information bias from patients regarding their prior allergic reactions. It also fails to
consider other types of antibiotic allergies in the beta-lactam family. Overall, this study shows
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that with ideal conditions and training, medical providers can safely and efficiently de-label PCN
allergy patients in the outpatient setting. That being said, further research regarding the
accelerated testing schedule would need to be performed to ensure safety and accuracy for any
resensitization of patients.
The Cost-effectiveness of PCN Allergy Testing
Concerns related to the cost-effectiveness of PCN allergy testing remain at the forefront
of health care analysts and health care systems. Variables related to resources, staff, and training
are all factors to consider when factoring the costs to benefits ratio of PCN allergy testing. To
understand the potential cost savings of PCN allergy testing one must first understand the basic
cost of the actual testing process.
Blumenthal et al. performed a study seeking to investigate the basic costs of PCN allergy
testing (2017). Specifically, they sought to evaluate the cost of PCN allergy evaluation using
time-drive-activity-based costing (TDABC). The TDABC is a method created by health care
economists to estimate costs using both the time spent using a specific resource and the per-unit
cost of that resource. This method has successfully been used to estimate costs in other health
care specialties. This evaluation was then compared with other cost estimating models, such as
the ratio of costs to charges method (RCC) and the relative value unit method (RVU). They
began the clinical trial using TDABC during the care of 30 outpatients being evaluated for PCN
allergies.
Results of the study using the TDABC method showed the following: estimated
personnel cost of $98, consumables cost of $119, and space cost of $3 for a PCN allergy
evaluation. This amounted to a total of $220 USD for a PCN allergy evaluation. The lowest and
highest TDABC estimates based on the type of provider, materials, time, and demand were $40
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and $537, respectively. Results of the RCC model revealed the estimated costs of PCN allergy
testing being $829. This included the cost of a new visit evaluation and management ($306) and
the procedure ($523). The range of estimated costs using the RCC model was $225 (no
evaluation and management and a two-step allergy test only) and $1,247 (two visits with a PCN
skin test using ampicillin and a two-step challenge after initial skin testing). Results of the RVU
model estimated PCN allergy testing being a total of $328 ($218 for evaluation and management
and $118 for the procedure). Overall, estimated costs using the RVU model ranged from $110
(no evaluation and management charge with a skin test and one step challenge) to $555 (two
visits with an ampicillin skin test and a two-step challenge after initial skin testing).
This study is helpful as it demonstrates the costs of PCN allergy testing using multiple
cost estimating models commonly used in health care. This study also is beneficial as it took
into consideration other variables outside of PCN allergy testing such as personnel, space for
testing, and consumables. Limitations of this study are that it does not include all of the costs
related to health care evaluation such as billing and other clinic staffing costs. Its study group
was also limited to only 30 patients. Lastly, it failed to address the varying costs of supplies
depending on the location and the amount of supplies being ordered.
Another study investigating the basic costs of PCN allergy testing was performed by
Kufel et al. (2019). They performed a systematic review of the different variables related to
PCN allergy testing in the outpatient setting. First, they performed a thorough review of the
available literature related specifically to PCN allergy testing in the outpatient setting as
performed by pharmacists. They searched PubMed using search terms such as skin tests,
penicillin, and outpatient.
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Their findings related to costs revealed that the median time necessary to perform a
detailed allergy history is 13.8 minutes and the median time to perform skin prick and
intradermal testing is 20 minutes. A one-step oral challenge with monitoring was 60 minutes or
more and a two-step oral challenge required a 30 minute plus 60-minute testing/ observation time
frame. Overall, the total time required for testing and observation was 45-120 minutes. They
also found the total cost of PST supplies to be between $140 to $160 per patient.
They also noted that outpatient PST is a reimbursable process with a CPT code of 95018
for each prick/ intradermal test, and 95076 for the oral ingestion challenge with a 61 to 120minute observation period. The CPT code of 95018 is reimbursed $18.95 on average by
Medicare and Medicaid services.
Limitations of this review are that it does not specifically investigate the costs of not
performing PCN allergy testing. It also focuses solely on pharmacists performing PCN allergy
testing as a means to reduce patient morbidity/ mortality and increase antibiotic stewardship.
Another weakness of this study is that the authors only utilized PubMed for their search of
available literature.
Next, it is important to evaluate the potential cost savings of performing confirmatory
PCN allergy testing when investigating the total cost-effectiveness of such testing. Mattingly et
al. performed a systematic review of studies evaluating the clinical and economic outcomes
associated with having a PCN allergy (2018). This was done in an attempt to provide
recommendations for future analyses regarding the cost-effectiveness of PCN allergy testing.
Their research included data from the databases SCOPUS, EMBASE, and PubMed. The results
of their research were limited to peer-reviewed publications in English that were published up to
the year 2017.
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Their review found that the total potential cost savings of de-labeling a patient in the
inpatient setting driven by the length of stay reductions was $1,145 to $4,254 per patient. They
also discovered a study demonstrating that PCN allergic patients were estimated to experience a
38% higher cost due to having more expensive medications at discharge from the hospital. The
average outpatient prescription costs of those patients with a PCN allergy were estimated to be
$14 to $193 per patient.
Limitations of this review are that it included studies outside of the United States, which
makes it hard to compare costs and health care protocols. Also, a majority of the studies it
included were of shorter observation lengths and failed to evaluate the costs related to missed
work and productivity losses in those patients with a documented PCN allergy. This review is
important as it shows the costs associated with longer hospital stays and more expensive
outpatient prescriptions in those with a PCN allergy.
Another cost savings investigation of PCN allergy testing was performed using follow up
with pediatric patients who were previously successfully de-labeled from having a PCN allergy
in a prior study. Vyles et al. performed a follow-up phone survey of the parents of the pediatric
patients and their primary care provider (PCP) (2018). A total of 100 pediatric patients’ parents
and PCP’s were interviewed. They then performed a three-tier economic analysis from
prescription information gathered by the survey to estimate actual cost savings, cost avoidance,
and potential cost savings of those pediatric patients having been successfully de-labeled.
Eighty-one percent of the 100 families contacted completed the follow-up survey. Of
those parents: 73 (90%) were aware of their child’s negative PCN allergy results and 65 (80%)
notified their child’s provider of their child’s negative PCN allergy results. Ninety-eight percent
of the PCPs completed the follow-up survey. Of those providers, 82 (84%) stated they were
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notified by the parents of their patients regarding their child’s negative PCN allergy results.
Fifty-one (52%) children still had a reported PCN allergy on their PCP medical record despite
being testing negative. The race of the pediatric patients was as follows: 24 (69%) white, 5
(14%) African American, and 4 (11%) Hispanic.
Thirty-six patients had filled at least one prescription since being de-labeled, and ten
patients had filled two prescriptions for a total of 46 prescriptions. The most commonly
prescribed antibiotic was amoxicillin and/ or PCN (n=24, 52%). Others prescribed by PCP’s
included azithromycin (n=13; 28%), cefdinir (n=6; 13%), amoxicillin with clavulanic acid (n=2;
4%), and cefadroxil (n=1; 2%). Of those prescriptions given by PCP’s, only one (4%) formerly
de-labeled child experienced a reaction (rash) approximately 24 hours after receiving
amoxicillin.
Results of the study revealed the cost savings of those 24 children receiving PCN and/ or
amoxicillin ($10 median price per prescription), as opposed to a nonpenicillin (average cost $70
per prescription), was $1,368.13. The cost avoidance was $1,812 (calculated on the basis that
the 24 PCN prescriptions would have likely been cefdinir instead). Lastly, the total potential
cost savings extrapolated to include 6700 pediatric patients with a PCN allergy being treated at
their pediatric emergency department per year was $192,223.
The de-labeling of PCN allergy in pediatric patients led to their PCP’s using more PCN’s
for follow up treatment. PCN’s are cheaper than most other more broad-spectrum antibiotics.
Ultimately, this led to a cost savings with using PCN’s versus if these children had been treated
with more expensive non-PCN antibiotics. Limitations of this study are that it involves data
within only one hospital system and a smaller study group as not all of the families could be
contacted for follow up. This means the study’s authors cannot guarantee one of those children
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not followed up with did not experience a severe allergic reaction. This study also fails to
consider the associated costs of PCN allergy testing or the longer-term savings associated with
being PCN allergy de-labeled.
This study shows both the safety of confirmatory PCN allergy testing and the potential
for cost savings with not having to prescribe other broader spectrum, expensive antibiotics. This
study is also beneficial in that it breaks down the actual cost savings, cost avoidance, and
potential cost savings on a large scale using PCN’s instead of other antibiotics.
Moussa et al.’s study referenced earlier in this review also evaluated the potential cost
savings of de-labeling surgical patients with a beta-lactam allergy (2018). Their study results
related to costs showed of those patients who tested positive for a beta-lactam reaction,
vancomycin was given to two patients instead of a beta-lactam, cefazolin in two patients,
clindamycin to two patients, and one patient did not receive any antibiotics. The use of
vancomycin instead of a beta-lactam resulted in a 59-minute mean time to first incision, 37
minutes with cefazolin, and 21 minutes with no antibiotics. Cefazolin use instead of vancomycin
reduced incision time delay by an average of 22 minutes. Study authors concluded this time
savings resulted in an overall cost savings of $42,240 in the 120 patients that were successfully
de-labeled and able to receive cefazolin. They then extrapolated this data and applied it to the
30,000 patients who receive surgery annually at their facility. They assumed an 11.5%
prevalence of suspected PCN allergy and of those patients 75% would likely require prophylactic
antibiotics. This equated to an estimated 2,587 preoperative allergy assessments, of which 996
could successfully be de-labeled and avoid having to use vancomycin. That time savings
ultimately equaled a saving of 365 hours of operating theater time and $350,867 Canadian
dollars (CAD) in direct costs annually.
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Macy and Shu’s study also referenced earlier in this review calculated the cost-benefit
ratio via the reduction of health care utilization in those patients who had performed PCN allergy
testing (2017). Their results showed -0.089 OPD visits per year at a per-visit cost of $145, 0.132 ED visits per year at a per-visit cost of $1,233, and -0.553 days spent in the hospital at
$3,146 per hospital day. This amounted to $1,915.40 less in health care expenses per patient per
year. They compared this to a one-time cost of PCN allergy testing at $145 which revealed a
possible health plan savings of over two million dollars over a period of 3.6 years. The minimal
cost and time needed to safely perform PCN allergy testing is a modest investment that can have
significant savings for patients and health systems alike.
Barriers to PCN Allergy Testing in the Outpatient Setting
As the research referenced so far has shown, incorrect PCN allergies are prevalent
throughout the world. It has also been shown that the risks of having an incorrect PCN allergy
label are significant when it comes to morbidity and mortality. Lastly, PCN allergy testing has
been well documented as being safe and cost-effective. The question remains then, why aren’t
more providers and patients having their vague or unclear PCN allergies confirmed with
outpatient PCN allergy testing? This next section will evaluate the barriers as to why
confirmatory PCN allergy testing is not being utilized more.
Recently, Jones and Kim performed a study to evaluate the current perceptions regarding
PCN allergies, perceived barriers to allergy clinic referrals, and formulate logical interventions
aimed at more outpatient referrals for PCN allergy testing (2019). Their study was done via
email (Survey Monkey Platform) sent to primary care physicians to evaluate their knowledge
related to PCN allergies and any perceived barriers to PCN allergy clinic referrals. Providers
from the University of California San Diego Department of Internal Medicine and Department of
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Family medicine were the target study group. A total of 204 providers were invited to complete
the email survey. Of those, 85 providers (42%) participated in the survey. This included 26
attending physicians and 59 resident physicians. The most commonly cited barriers by providers
to allergy clinic referrals for PCN allergy evaluation included the following: “Patients have
multiple other medical problems which take priority in time-limited encounters” (41%), “I did
not realize that this service was available for my patients” (26%), “I am concerned that the
allergy history is inaccurate or unclear” (12%), “I don’t think my patients will follow through
with the referral” (5%), and “Other” (16%)” (Jones & Kim, 2019). Educational intervention
training was offered with 19 primary care providers participating. Following the training, 12
(63%) residents stated that an alert visible to patients on an EMR portal prompting patients to
discuss their PCN allergy with their provider would help increase allergy referrals and that it
would not be a burden on their overall practice. Eleven residents (58%) responded that they
would be interested in a smartphone application that detailed the best practice for patients with
PCN allergies and appropriate questions for a referral to help increase PCN allergy referrals.
After the educational intervention, the total of referrals for PCN allergy testing remained
relatively unchanged with 24 referrals before the intervention and 25 after the intervention.
This study highlights the barriers, both real and perceived, that deter providers from
referring patients for confirmatory PCN allergy testing. The study also hints at the possible
benefits of educating primary care providers regarding the benefits of PCN allergy testing and
the possible realistic interventions that could help providers, patients, and allergists come
together for the benefit of the patients and the medical community abroad. Limitations of this
study were its limited pool of participants from a single medical community. It also only
targeted providers from one specialty.
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Another study investigating barriers and perceptions regarding PCN allergy testing was
performed by Trubiano et al. (2016). The authors surveyed members of the Emerging Infections
Network (EIN) of The Infectious Diseases Society of America (IDSA) to evaluate the current
availability of antibiotic allergy evaluation services and the overall receptiveness for initiating
antibiotic allergy testing (AAT) strategies into programs to encourage proper antibiotic
stewardship. A ten-item survey was created and distributed to EIN members between September
15th and October 13th of 2015. A total of 736 of 1545 (48%) of respondents were active EIN
members with 558/736 (75%) being adult physicians, 154/ 736 (20%) being pediatricians, and
24/736 (3.2%) being both. A majority of respondents (500/736; 68%) estimated the prevalence
of PCN allergy to be between 5 to 20% of their patient populations. Forty-three percent
(317/736) of physicians had SPT or IDT available to them and only 27% (204/736) had SPT and
IDT combined with an oral challenge available. It is noted in the study that SPT/IDT with a
combined oral challenge is currently considered the gold standard for PCN allergy testing.
Twenty-three percent (171/736) of respondents did not have access to any form of allergy testing
in their practice areas. Lastly, it was found that of those who did have antibiotic allergy testing
(AAT) services, 40% (182/460) were unaware of the specific types of testing actually available
to them.
Respondents noted that AAT was most frequently performed in outpatient facilities in
their practice areas with 274/432 (63%) stating as such. There was also a large number of
respondents who offered testing in either an inpatient setting (202/432; 47%) and/ or an intensive
care setting (218/432; 50%). It was revealed that a majority of providers believed it was of value
to refer patients for allergy testing (410/442; 93%) and that they believed confirmatory allergy
testing would be successful in removing patients’ antibiotic allergy label (336/432; 78%). It was
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also interesting to find that respondents with less than 15 years’ experience were more likely
than respondents with ≥ 15 years’ experience to believe in the overall effectiveness of antibiotic
testing in removing an antibiotic allergy label from patients (82%; 198/241 vs. 63%; 138/219
with p=0.0001).
Interestingly, in the instance that a patient had a “remote” history of PCN allergy and
where treatment with PCN would be the preferred therapy, respondents of the study stated they
would provide treatment as follows: “(1) point-of-care testing (40%, 177 of 442); (2) use of an
alternative non-β-lactam antibiotic, even if inferior (13%, 57 of 442); (3) desensitization with
maintenance of penicillin allergy label (8%, 37 of 442); or (4) desensitization then allergy clinic
referral for penicillin allergy testing (7%, 30 of 442)” (Trubiano et al., 2016). Lastly, most
physicians (277/446; 62%) included in the study replied that they believed antibiotic allergy
testing in an effort to de-label patients would improve general practice behavior by using more
appropriate antibiotics, causing safer administration of antibiotics, and ultimately causing
improved antibiotic stewardship practices.
This study includes an impressive number of physician respondents and their beliefs
regarding AAT. A large number of providers believed in the ability of AAT to enhance
antibiotic stewardship practices. Unfortunately, only 43% had actual testing available to them
and their patients. It was also surprising to find that ID providers with increased experience were
less likely to believe in AAT. This information further helps define the barriers and beliefs
related to PCN allergy. Some of the limitations of this study involve its target study group. It
was mainly directed toward physicians associated with the EIN, rather than primary care
providers outside of an infectious disease subspecialty. This causes population bias as it skips
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other members of the health care team, including immunologists and allergists. There is also
likely selection bias due to the targeted EIN population being more likely to answer the survey.
In summary, this study provides a large amount of data related to the barriers regarding
the implementation of PCN allergy testing in the outpatient setting. The study also provided a
sizeable test group that showed a great amount of support for confirmatory allergy testing.
However, there are gaps when it comes to the availability of skilled testing facilities and
deficiencies in providers’ knowledge about the availability of testing resources in their areas.
Overall, providers are willing to refer patients for allergy testing because they believe it is a
necessary step for appropriate antibiotic stewardship.
Discussion
The most recent research shows significant numbers of patients having an incorrect PCN
allergy label. This may be due to poor patient recall, poor electronic documentation, or vague
reactions that were not actually allergic reactions to a PCN related antibiotic. It is also
noteworthy to mention again that even those patients who have been correctly identified as
having a PCN allergy will eventually lose their initial allergy to PCN's after a period of ten years
(Kufel et al., 2019). This may also contribute significantly to the prevalence of incorrect PCN
allergy labels. Several studies in this review demonstrated a majority of patients testing negative
for a documented PCN allergy when properly tested. This included Kleris et al.’s study during
which 91.3% of the 104 study participants with a documented PCN allergy actually tested
negative when properly tested (2018). Moussa et al. had similar results with their study in
which 94.3% of the 194 study participants were de-labeled as having a PCN allergy when tested
(2018). These two studies echo the statistics presented by Kufel et al. in that 90% of the 10% of
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Americans with a documented PCN allergy when properly tested are negative for a PCN allergy
(2019).
The presence of an incorrect PCN allergy label forces health care providers to use
antibiotics not related to PCN’s. These alternative antibiotics are often unnecessarily more
broad-spectrum antibiotics that can lead to increased incidences of CDI and MRSA. These
infections result in patients having to be hospitalized more frequently and can even lead to death.
West et al. showed this with their study results in that a PCN allergy record was associated with
six in 1000 more deaths and one in 1000 more patients with documented MRSA infections
(2019). Blumenthal et al.’s study results also showed a significant increase in the incidence of
MRSA in patients with a documented PCN allergy (2018). Specifically, having a PCN allergy
label caused a 68% increased risk of MRSA and also a 26% increased risk for CDI. It was also
noted that the use of non-PCN related antibiotics accounted for 55% of the increased risk for
MRSA and 35% for the increased risk of CDI. Other studies such as Macy and Shu’s showed
that those patients who had been successfully de-labeled as having a PCN allergy averaged 0.09
fewer OPD visits, 0.55 fewer hospital days, and 0.13 fewer ED visits (2017). This supports other
data describing PCN labeled patients having more health care visits and longer hospital stays.
IgE mediated allergic reactions to PCN are the swiftest and most dangerous type of
reactions patients can possibly experience. Patients are extremely hesitant to undergo
confirmatory PCN allergy testing in the outpatient setting for this reason. The work performed
by Bourke et al. (2015) demonstrated the safety and accuracy of PCN allergy testing. In their
study, skin prick testing and intradermal testing for PCN allergies had a negative predictive value
of 99.2%. Also, of the 137 patients they were able to follow up with, only 17 experienced a
subjective adverse reaction. Another study demonstrated 770 of the 880 children who received
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confirmatory PCN allergy testing were safely delabeled from having a PCN allergy (Mill et al.,
2016). It was also discovered that the graded PC had a specificity of 100.0% (95% CI, 90.9100.0%), a NPV of 89.1%, and a positive predictive value (PPV) of 100.0% (95% CI, 86.3%100.0%). This shows the high levels of accuracy and safety when considering PCN allergy
testing.
The process of testing patients to confirm a PCN allergy can avoid increased health care
costs for patients and health systems by avoiding increased levels of morbidity and mortality
associated with using antibiotics not related to PCN’s. Estimated costs for a confirmatory PCN
allergy testing range from $40 to $537 (Blumenthal et al., 2017). This is a minimal investment
when one considers the potential cost savings of having testing performed. Multiple studies
referenced in this review showed a cost saving for patients with a documented PCN allergy who
had PCN allergy testing performed compared to those who did not. These included inpatient
length of stay reduction savings of $1,145 to $4,254 (Mattingly et al., 2018), a prescription
savings of $1,368 (Vyles et al., 2018), and an overall surgical savings of $42,240 for those
surgical patients who had PCN allergy testing performed prior to surgery (Moussa et al., 2018).
The most significant cost savings was described in the study performed by Macy and Shu (2017).
Their study showed patients who had PCN allergy testing performed resulted in $1,915.40 less in
health care expenses per patient per year. Which when compared to the one-time cost of PCN
allergy testing at $145 and extrapolated across their health system revealed a possible health
savings of over two million dollars over a period of just 3.6 years.
If PCN allergy testing is safe, accurate, and cost-effective, then why are not more patients
and providers in favor of it? The studies reviewed showed this is largely due to the incorrect
patient and provider perceptions regarding the availability, safety, and costs related to
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confirmatory PCN allergy testing. It was discovered in one study that 40% of the medical
providers were unaware of the specific types of PCN allergy testing available to them (Trubiano
et al., 2016). Another study performed by Jones and Kim revealed the different perceptions
medical providers had regarding PCN allergy testing (2019). Of those medical providers
surveyed in the study: 41% felt they did not have the time to address PCN allergy testing during
their patient encounters, 26% were not aware PCN allergy testing was available to them, and
12% felt concerned that their patient’s PCN allergy history was vague or unclear. Both of these
studies highlight some misunderstandings and need for further education about PCN allergy
testing for medical providers. If medical providers are properly educated regarding the
availability and benefits of PCN allergy testing in their health systems they can then begin to
educate their patients and bring about significant positive change.
In conclusion, would confirmatory PCN allergy testing in the outpatient setting versus
using more broad-spectrum antibiotics not related to PCN's be more cost-effective and safer in
limiting overall patient morbidity and mortality? The research shows that PCN allergy testing in
the outpatient setting is a safe and accurate method of confirming a patient’s PCN allergy status.
The costs associated with testing are minimal compared to the increased costs of having to use
more expensive broad-spectrum antibiotics that can cause infections and increased hospital stays.
The data shows a significant portion of the population is incorrectly labeled as having a PCN
allergy. If medical providers can begin to educate their patients regarding the benefits of
confirmatory PCN allergy testing we can significantly reduce the increased costs, morbidity, and
mortality with having an incorrect PCN allergy label.
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Applicability to Clinical Practice
With the information provided by this literature review, both clinicians and patients will
be able to make a safe and informed decision regarding performing confirmatory allergen testing
in the presence of an unclear or unconfirmed PCN allergy. The decision to perform confirmatory
PCN allergy testing based on unbiased, evidence-based medicine could lead to reduced health
care costs, improved patient outcomes, and decreased adverse effects related to prescribing
alternative, more broad-spectrum antibiotics instead of PCN’s. It is also important to mention
that proper antibiotic stewardship demands the precise prescribing of the narrowest spectrum
antibiotic that will effectively treat the patient’s infection. Having patients undergo confirmatory
PCN allergy testing in an effort to avoid having to use more broad-spectrum antibiotics is a
necessary step health care providers need to perform in order to improve patient care, reduce
costs, and reduce overall antibiotic resistance.
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